MetaCap

PepGen (PEPG) vs Phathom Pharmaceuticals (PHAT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PepGen (PEPG) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 32.0% versus a loss of 68.9%. Phathom Pharmaceuticals is the larger company by market cap ($378.8 million vs $356.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PEPG-32.01%PHAT-68.93%
+34%-23%-81%
Nov 21, 20251 yearNov 20, 2026
PEPG-70.67%PHAT-59.51%
+68%-16%-99%
May 2, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PEPG versus PHAT key metrics
MetricPEPGPHAT
Share price$3.78$4.66
Market cap$356.31M$378.82M
1-day change-3.82%-8.27%
YTD return-41.94%-71.91%
1-year return-32.01%-68.93%
5-year return—-76.46%
Forward P/E—5.18
EPS (TTM)$-0.77$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$175.11M
Revenue growth (YoY)—+216.93%
Net income (latest FY)$-89.66M$-221.25M
Gross margin—87.09%
Operating margin—-91.36%
Net margin—-126.35%
52-week high$7.80$18.31
52-week low$1.31$4.62
Distance from 52-week high-51.54%-74.55%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+263.76%+321.67%
Average volume3.26M1.45M
Shares outstanding94.26M81.29M
Employees53371
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PEPG has outperformed PHAT by 36.9 percentage points over the past year.

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

About Phathom Pharmaceuticals

PHAT stock →

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees

PEPG vs PHAT FAQ

Which is bigger, PepGen or Phathom Pharmaceuticals?

Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $378.82M compared with $356.31M for PepGen (PEPG).

Which stock has performed better over the past year, PEPG or PHAT?

PEPG returned -32.01% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.

Are PepGen and Phathom Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons